- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
Patent holdings for IPC class A61P 7/00
Total number of patents in this class: 2794
10-year publication summary
|
63
|
75
|
149
|
139
|
167
|
199
|
164
|
229
|
222
|
124
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Alexion Pharmaceuticals, Inc. | 636 |
40 |
| Novartis AG | 10741 |
36 |
| Global Blood Therapeutics, Inc. | 181 |
33 |
| The Regents of the University of California | 19989 |
28 |
| Takeda Pharmaceutical Company Limited | 2711 |
27 |
| Acceleron Pharma Inc. | 360 |
24 |
| Bayer Pharma AG | 1052 |
18 |
| Jiangsu Hengrui Medicine Co., Ltd. | 708 |
18 |
| Children's Medical Center Corporation | 1877 |
17 |
| Shanghai Hengrui Pharmaceutical Co., Ltd. | 643 |
17 |
| Daiichi Sankyo Company, Limited | 1878 |
16 |
| F. Hoffmann-La Roche AG | 7945 |
15 |
| President and Fellows of Harvard College | 5993 |
15 |
| University of Pittsburgh - Of the Commonwealth System of Higher Education | 3171 |
15 |
| The University of Tokyo | 4193 |
15 |
| Bristol-myers Squibb Company | 4881 |
14 |
| Vertex Pharmaceuticals Incorporated | 1602 |
14 |
| Nippon Shinyaku Co., Ltd. | 322 |
13 |
| Dana-Farber Cancer Institute, Inc. | 2574 |
12 |
| Omeros Corporation | 306 |
12 |
| Other owners | 2395 |